Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1326-1795 | Other Identifier | World Health Organization (WHO) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to evaluate the association of once-weekly semaglutide with the risk of cardiovascular (CV) and other obesity-related clinical outcomes in three study populations (Heart failure (HF), clinical Atherosclerotic Cardiovascular Disease (ASCVD), primary prevention).
This is a retrospective cohort study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for participants in the US during January 1, 2016 - December 31, 2024.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort: Semaglutide users |
| ||
| Cohort: Semaglutide Non-users |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No treatment given | Other | No treatment given |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Revised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event) | Measured as Months Occurrence of any of the following individual component events:
The event date will be the earliest occurrence of one of the individual components. | Index date, earliest of revised MACE-5 and end of follow-up; up to 42 months |
| Revised 3-point Major Adverse Cardiovascular Events MACE-3 (time-to-event) | Measured in Months Occurrence of any of the following individual component events:
The event date will be the earliest occurrence of one of the individual components. | Index date, earliest of revised MACE-3 and end of follow-up; up to 42 months |
| Measure | Description | Time Frame |
|---|---|---|
| MI (time-to-event) | Measured as Months A primary diagnosis of MI (identified using International Classification of Disease, 10th Edition, Clinical Modification (ICD-10-CM) diagnosis codes observed during an inpatient (IP) visit). The event date will be admission date of the IP visit. | Index date, earliest of MI and end of follow-up; up to 42 months |
Not provided
Inclusion Criteria:
1. HF: Diagnosis of HF 2. Clinical ASCVD: Diagnosis or procedure codes indicating:Coronary artery disease (CAD) including acute coronary syndrome (ACS; i.e., myocardial infarction [MI] or unstable angina), stable angina, coronary or other arterial revascularization or intervention, ischemic stroke, transient ischemic attack (TIA), carotid or other arterial stenosis, peripheral arterial disease (PAD) including aortic aneurysm 3. Primary Prevention: Patients at risk for developing ASCVD defined as the presence of more than or equal to (≥) 3 of the following risk factors
3. Participants who are more than or equal to (≥) 45 years old by December 31, 2024
4. Participants will be divided into the following groups: those who initiate semaglutide on or after the eligibility date and June 4, 2021 (semaglutide users; date of initiation termed the index date) or participants with no evidence of semaglutide usage during January 1, 2016 to December 31, 2024 (non-users; a randomly selected date with ≥ 1 pharmacy claim on or after the eligibility date and June 4, 2021 will be termed the index date)
5. Participant with continuous insurance enrolment eligibility more than or equal to (≥) 12 months prior to the index date (the baseline period)
6. Participants with re-confirmed overweight/obesity indication during the baseline period
Exclusion Criteria:
1. Population specific exclusion criteria:
2. Participants with a diagnosis of chronic or acute pancreatitis
3. Participants with a diagnosis of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
4. Participants with end-stage kidney disease (ESKD) including chronic or intermittent haemodialysis or peritoneal dialysis and/or kidney transplant
5. More than or equal to (≥ 2) diagnoses of cancer (excluding non-melanoma skin cancer)
6. Pregnancy in female participants
7. Evidence of diabetes including more than or equal to (≥) 2 diagnoses of type 1 diabetes or more than or equal to (≥) 2 diagnoses of type 2 diabetes on distinct dates, use of a glucose-lowering agent, and/or glycated haemoglobin (HbA1c) laboratory result more than or equal to ≥ 6.5 percent (%)
8. Use of a glucagon-like peptide-1 (GLP-1) or GLP-1/gastric inhibitory polypeptide (GIP) receptor agonist approved for weight management during the baseline period
9. Participants with evidence of bariatric surgery
Not provided
Not provided
Not provided
This study aims to evaluate the association of once-weekly semaglutide with the risk of CV and other obesity-related clinical outcomes in three study populations. This is a retrospective cohort study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for participants in the US during January 1, 2016 - December 31, 2024.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Clinical Transparency dept. 2834 | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novo Nordisk Investigational | Plainsboro | New Jersey | 08536 | United States |
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| No treatment given |
| Other |
No treatment given |
|
| Stroke (time-to-event) | Measured as Months A primary diagnosis of stroke, including both ischemic and haemorrhagic, (identified using ICD-10-CM diagnosis codes observed during an IP visit). The event date will be the admission date of the IP visit. | Index date, earliest of stroke and end of follow-up; up to 42 months |
| Hospitalization for HF (time-to-event) | Measured as Months A primary diagnosis of HF (identified using ICD-10-CM diagnosis codes observed during an IP visit). The event date will be the first observed admission date of the IP visit. | Index date, earliest of hospitalization for HF and end of follow-up; up to 42 months |
| Coronary revascularization (time-to-event) | Measured as Months Evidence of coronary revascularization in any claim (identified using International Classification of Disease, 10th Edition, Procedure Coding System (ICD-10-PCS), Current Procedural Terminology (CPT), or Healthcare Common Procedure Coding System (HCPCS) procedure codes). The event date will be the first observed date of coronary revascularization. | Index date, earliest of Coronary revascularization and end of follow-up; up to 42 months |
| All-cause mortality (time-to-event) | Measured as Months Evidence of death as recorded at the month and year level in Komodo Research Data (KRD) and defined as a death record observed within the last month of follow-up. The event date will be the earliest of the end of follow-up (e.g., bariatric surgery within the month of death and last month of follow-up) or the last day of the recorded month of death. | Index date, end of follow-up; up to 42 months |
| MACE-5 (time-to-event) | Measured as Months Occurrence of any of the following individual component events:
The event date will be the earliest occurrence of one of the individual components. | Index date, earliest of MACE-5 and end of follow-up; up to 42 months |
| MACE-3 (time-to-event) | Measured as Months Occurrence of any of the following individual component events:
The event date will be the earliest occurrence of one of the individual components. | Index date, earliest of MACE-3 and end of follow-up; up to 42 months |
| CV-related mortality (time-to-event) | Measured as Months Any claim within ≤30 days before the date of death (i.e. the last day of the recorded month of death, where death is observed in the last month of follow- up) of the following operational definition to indicate CV related mortality:
The event date will be the earliest of the end of follow-up (e.g. bariatric surgery within the month of death) or the date of death. | Index date, end of follow-up; up to 42 months |
| Urgent HF visit (time-to-event) | Measured as Months A primary diagnosis of HF (identified using ICD-10-CM diagnosis codes observed during a non-IP visit). Further, at least one the following interventions must be observed in a non-IP claim on the same day as the non-IP visit:
The event date will be the first observed date of the non-IP visit that meets the urgent HF criteria. | Index date, earliest of urgent HF visit and end of follow-up; up to 42 months |
| 3-point HF (time-to-event) | Measured as Months Occurrence of any of the following individual component events:
The event date will be the earliest occurrence of one of the individual components. | Index date, earliest of 3-point HF composite outcome and end of follow-up; up to 42 months |
| 2-point HF (time-to-event) | Measured as Months Occurrence of any of the following individual component events:
The event date will be the earliest occurrence of one of the individual components. | Index date, earliest of 2-point HF composite outcome and end of follow-up; up to 42 months |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D009765 | Obesity |
| D006333 | Heart Failure |
| D050197 | Atherosclerosis |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided